Book Value per Share: kalarx.com (KALA)

Graphic logo of KALA BIO (KALA)

KALA BIO, Inc. (KALA) is actively implementing stem cell technologies to develop advanced corneal restoration methods. The asset's price trajectory shown below complements data on clinic partnerships aimed at accelerating the commercialization of new formulas. The current metric stands at 0.47. The business's financial performance is based on the sale of patented anti-inflammatory drops and innovative treatments for ocular pathologies.

Kala Pharmaceuticals (KALA): Share Book Value from 07/04/2022 to 10/28/2026

KALA BIO Inc. - analytical breakdowns and key metrics (KALA)

- price and consensus price forecast:
Price Chart Kala Pharmaceuticals|KALA - Price Target Chart
- market capitalization data:
Market Capitalization KALA BIO, Inc.|KALA - Enterprise Value
- book capitalization data:
Net Assets per Single Share KALA BIO|KALA - Net Asset Value|Market Capitalization to Book Value Ratio kalarx.com|KALA - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital KALA BIO, Inc.|KALA - Long-Term Debt to Capital|Short-Term Debt to Equity Kala Pharmaceuticals|KALA - Aggregate Debt Obligations|Debt to Book Capitalization Ratio KALA BIO, Inc.|KALA - Company Long-Term Liabilities|Company Short-Term Debts KALA BIO
Fundamental company valuation:kalarx.com - KALA
Manufactured products of Kala Pharmaceuticals

This indicator reflects the net asset value of KALA BIO, Inc. minus all liabilities, allocated per share, allowing for an assessment of the business's intrinsic value. The trend in book value per share demonstrates the financial stability of KALA BIO, Inc. as it develops innovative secretome-based corneal regeneration drugs, confirming the availability of solid capital to execute its research and development programs.

Competitors of KALA BIO, Inc. (KALA)

ALC - Net Assets per Single Share|BLCO - Net Assets per Single Share|GKOS: Book Value per Share|APLS (apellis.com) - Book Value per Share|Net Assets per Single Share belitebio.com BLTE|Share Book Value Ocular Therapeutix Inc|Harrow Health (HROW) - Book Value per Share|Accounting Value of a Share Viridian Corp (VRDN)|Book Value per Share LENZ (LENZ Therapeutics, Inc.)|Oculis Pharma - Book Value per Share|Net Assets per Single Share EyePoint Pharmaceuticals, Inc. (EYPT)|KOD: Accounting Value of a Share|ALDX (aldeyra.com) - Net Assets per Single Share|Opus Genetics (IRD) - Accounting Value per Share|OKYO (OKYO Pharma Ltd) - Book Value per Share|Book Value per Share Adverum (ADVM)|Outlook Therapeutics, Inc. (OTLK) - Accounting Value per Share|Accounting Value of a Share Clearside Biomedical Inc (CLSD)|NBY: Book Value per Share|KPRX - Net Asset Value per Share|ALIM (Alimera) - Accounting Value per Share|EYEN - Net Asset Value per Share|Book Value per Share GHSI|OCUP (Ocuphire Pharma Inc) - Net Asset Value per Share|OPT: Net Assets per Single Share